The role of the ubiquitination-proteasome pathway in breast cancer: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer by Orlowski, Robert Z & Dees, E Claire
1
HIV = human immunodeficiency virus; MAPK = mitogen-activated protein kinase; MDR = multidrug resistance; MKP = MAPK phosphatase; NF-κB
= nuclear factor-κB; SUMO = small ubiquitin-like modifier 1; Top-1 = topoisomerase 1.
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Introduction
Function of the ubiquitin-proteasome pathway is essential
for many fundamental cellular processes, including the
regulation of receptor signaling pathways and the timely
degradation of cyclins, cyclin-dependent kinases, and
cyclin-dependent kinase inhibitors during mitosis. In addi-
tion, ubiquitin-proteasome activity is necessary for antigen
processing, angiogenesis, and apoptosis and for process-
ing and degradation of misfolded and short-lived regula-
tory proteins such as transcription factors. This pathway
consists of the ubiquitin-conjugating machinery (including
an E1 ubiquitin-activating enzyme) and many E2 and E3
ubiquitin-conjugating and ubiquitin-ligase proteins (Fig. 1).
The latter are responsible for transferring the activated
ubiquitin moieties from E1 to specific sets of proteins,
which are thereby targeted for degradation. It is the 26S
proteasome, which contains the proteins responsible for
proteolysis in a 20S core, that is responsible for degrada-
tion of these ubiquitinated products. Recent studies have
also identified an increasing number of proteins that are
subject to degradation through the 20S proteasome
without prior ubiquitination.
The possibility of targeting the ubiquitin-proteasome
pathway therapeutically was met in the past with skepti-
cism, because of concerns that this approach would be
inimical to life itself because of the important role played
by the proteasome in normal cellular homeostasis. With
the first demonstration that proteasome inhibitors were
well tolerated and had activity in models of human malig-
nancies in vivo [1], however, and the use in Phase I safety
trials of inhibitors (such as PS-341 [2]) that showed
acceptable toxicity with significant clinical benefit [3], tar-
geting the ubiquitin-proteasome pathway for cancer
The ubiquitin-proteasome pathway is responsible for most eukaryotic intracellular protein degradation.
This pathway has been validated as a target for antineoplastic therapy using both in vitro and
preclinical models of human malignancies, and is influenced as part of the mechanism of action of
certain chemotherapeutic agents. Drugs whose primary action involves modulation of ubiquitin-
proteasome activity, most notably the proteasome inhibitor PS-341, are currently being evaluated in
clinical trials, and have already been found to have significant antitumor efficacy. On the basis of the
known mechanisms by which these agents work, and the available clinical data, they would seem to be
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with current chemotherapeutics, may well represent important advances in the therapy of patients with
breast cancer.
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therapy has become an area of intense investigation. This
pathway may already play a major role in the therapy of
patients with breast cancer who receive anthracyclines.
For example, doxorubicin (Adriamycin) binds to subunits of
the 20S proteasome, which then translocates to the
nucleus [4], thereby acting as a carrier for this drug to
exert many of its cytotoxic effects. Several other agents,
however, influence either ubiquitination or proteasome-
mediated degradation (Table 1), and can be divided into
those that act indirectly, at steps prior to this pathway, or
directly on some pathway component. This article will
review the current status of these drugs, with a focus on
their potential application to clinical care of breast cancer.
Drugs with indirect effects
Increasing ubiquitin-proteasome function
Several drugs that stimulate ubiquitin-proteasome
pathway mediated degradation of a target protein in
another disease have been evaluated in breast cancer. All-
trans retinoic acid, an important step forward in the
therapy of acute promyelocytic leukemia, may in part work
by redistributing the promyelocytic leukemia-retinoic acid
receptor oncoprotein, accelerating its proteasome-medi-
ated degradation [5]. All-trans  retinoic acid has been
studied in patients with metastatic breast cancer and
found not to have significant activity, but in combination
with tamoxifen some responses were noted [6]. Whether
Figure 1
Protein degradation through the ubiquitin (Ub)-proteasome pathway. Most proteins that are destined for degradation through the Ub-proteasome
pathway are first subjected to polyubiquitination. This is accomplished in several stages. (a) The E1 Ub-activating enzyme, in an ATP-dependent
reaction, forms an activated complex with Ub and transfers it to the E2 Ub-conjugating protein. (b) The E2 Ub-conjugating protein then transfers
Ub to an E3 Ub-ligase protein, which has formed a complex with the target protein. In some cases an E3 Ub-ligase may not be necessary. (c) After
several cycles of ubiquitination, the polyubiquitinated target protein is recognized by the proteasomal cap proteins (shaded gray and labeled 19 S
cap) through its ubiquitin moieties, which are cleaved off by isopeptidases and recycled. (d) In an ATP-dependent fashion the protein is then
unwound and fed into the 20S core through an interior channel, where it is exposed to the active proteolytic enzymes (shaded black). (e)
Oligopeptide digestion products (OP) are then released and degraded further to amino acids by oligopeptidases. Some proteins may be subject to
proteasomal degradation without the need for prior ubiquitination. Please note that this schematic diagram does not represent the various
components to scale. Interested readers are referred to several excellent recent reviews with more detailed descriptions of this pathway [43,44].
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these effects in breast cancer are mediated through an
impact on the proteasome, however, is not known.
More clearly proteasome-related is the anticancer effect of
the camptothecins, which block the religation step of the
topoisomerase-1 (Top-1) reaction, and stimulate ubiquiti-
nation and subsequent proteasomal Top-1 degradation
[7]. Several camptothecin derivatives have been studied in
Phase I trials, and occasional responses in breast cancer
patients have been noted. Although Phase II results have
been generally disappointing, a recent study of irinotecan
in patients with refractory metastatic breast cancer
showed a 29% response rate, and tolerable toxicity [8].
Several interesting compounds under development are
based on geldanamycin, which inhibits the ATPase activity
of the heat shock chaperone protein HSP90. This leads to
the degradation of client proteins via the ubiquitin-protea-
some pathway, and since these include the c-erbB-2
(HER-2/neu) receptor protein-tyrosine kinase [9], their
potential application to breast cancer therapy is clear.
Analogues such as 17-allylamino-17-demethoxygeldana-
mycin are now in Phase I clinical trials.
Another agent in this category is the pure estrogen antag-
onist fulvestrant (Faslodex®), which has been approved for
use by postmenopausal patients with estrogen-receptor-
positive breast cancer who have progressed following
other anti-estrogen therapy (reviewed in [10]). This drug
appears to work in part by enhancing proteasome-depen-
dent degradation of estrogen receptor α [11]. Since some
estrogen agonists appear to have a similar activity with
respect to estrogen receptor α [11], it would be interest-
ing to determine if part of the well-known activity of tamox-
ifen and other hormonal agents is also due to a similar
impact on the proteasome.
Inhibition of ubiquitin-proteasome function
Arsenic trioxide is an example of a drug that acts indirectly
on the ubiquitin-proteasome pathway. It modifies a critical
cysteine residue in the activation loop of the IκB kinase,
preventing IκB phosphorylation. Subsequent IκB degrada-
tion is prevented, because degradation through the
ubiquitin-proteasome pathway normally follows
phosphorylation. Arsenic, therefore, indirectly inhibits
NF-κB activation [12]. As detailed below, activation of
NF-κB by chemotherapeutic agents and radiation is anti-
apoptotic. In addition, arsenic has been reported to specif-
ically inhibit expression and signaling through the estrogen
receptor pathway [13]. Arsenic trioxide, therefore, may
warrant further study in breast cancer either alone, or in
combination with other agents, and a variety of Phase I
and Phase II trials are underway.
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Table 1
Drugs that influence ubiquitin-proteasome activity
Drug class Action and mechanism
Chemotherapeutic agents
Aclarubicin Inhibits the chymotrypsin-like proteolytic activity of the proteasome
All-trans retinoic acid May accelerate PML fusion protein degradation through the proteasome
Arsenic trioxide Inhibits ubiquitination and degradation of IκB through effects on the IκB kinase
Camptothecin Stimulate ubiquitination and degradation of topoisomerase 1
Geldanamycin Inhibits HSP90 ATPase, stimulating proteasomal degradation of client proteins
PS-341/LDP-341/MLN-341 Inhibits the chymotrypsin-like activity of the proteasome
Vinblastine, Vincristine Inhibit the chymotrypsin-like, trypsin-like- and peptidyl-glutamyl peptide hydrolyzing proteasome activities
Immunosuppressive agents
Cyclosporine A Uncompetitive inhibitor of the proteasomal chymotrypsin-like activity
Rapamycin Inhibits proteasome function by inhibiting the proteasome activator PA28
Miscellaneous agents
Fulvestrant Stimulates proteasome-dependent proteolysis of ERα
Tannic acid Inhibits the chymotrypsin-like activity of the proteasome
Lovastatin Mechanism unknown, but appears structurally similar to the proteasome inhibitor lactacystin
Anti-retroviral drugs Inhibit the chymotrypsin-like and trypsin-like proteasome activities
ER, estrogen receptor; HSP, heat shock protein; PML, promyelocytic leukemia.4
Drugs with direct ubiquitin-proteasome
effects
Drugs with targets other than the proteasome
All of the agents that have been noted to have a direct
impact on ubiquitin- and proteasome-mediated proteolysis
have been proteasome inhibitors. Since some of these
were originally directed against other targets, they will be
discussed separately from those which were designed to
specifically inhibit the proteasome. In the former category
are dietary compounds such as tannic acid [14], antiretro-
viral agents including the HIV protease inhibitors [15,16],
and lipid-lowering agents, such as lovastatin [17], that
inhibit the proteasome, although possible applications to
breast cancer have not been investigated.
The immunosuppressive agent cyclosporine A is an
uncompetitive proteasome inhibitor [18], but in the breast
cancer setting it has been used predominantly to block
cytochrome-P450-mediated drug resistance, or to induce
graft-versus-host disease when patients have undergone
high dose chemotherapy, followed by autologous bone
marrow or peripheral blood stem cell rescue. Perhaps
more interesting is another immunosuppressive,
rapamycin, which inhibits expression of the proteasome
activator PA28, and thereby inhibits proteasome function
[19]. Since rapamycin blocks the estrogen-driven transi-
tion of breast cancer cells from the G1 to S phases of the
cell cycle [20], further studies in breast cancer may be
warranted.
Chemotherapeutic agents have been identified which
inhibit the proteasome, including aclarubicin (aclacino-
mycin A) [21], and vinblastine and vincristine [22], though
it is unclear if, in the case of aclarubicin, this occurs at
clinically relevant drug concentrations. Aclarubicin, an
anthracycline derivative, has been evaluated in several
Phase I and Phase II trials with generally disappointing
results, though none were targeted towards breast cancer
patients. The vinca alkaloid vinorelbine (Navelbine®),
however, has well-documented activity in breast cancer
[23], and it would be interesting to determine if this activity
is a result of proteasome inhibition.
Proteasome-targeted drugs
Inhibitors of the proteasome were first synthesized two
decades ago, and were initially used as laboratory tools to
probe the proteolytic activities of this complex (reviewed in
[24]) and its role in cellular processes. Subsequent inves-
tigations indicating these inhibitors were able to activate
programmed cell death in a variety of human tumor-
derived cell lines (reviewed in [25]) raised interest in such
agents as possible cancer chemotherapeutics. Several
lines of evidence suggest that proteasome inhibitors
would be active agents in patients with breast cancer.
From a mechanistic perspective, the transcription factor
NF-κB, an important regulator of apoptosis, can be consti-
tutively activated in several cancers, including some breast
cancers (reviewed in [26]). As mentioned above, protea-
some inhibitors work in part by blocking degradation of
the inhibitory protein IκB, thereby decreasing NF-κB
nuclear translocation [25]. Therefore, malignancies with
high levels of activated NF-κB, such as breast cancer,
should be especially sensitive to interruption of this
pathway, which would induce tumor cell death.
A second, recently elucidated, mechanism by which pro-
teasome inhibitors effect apoptosis is by decreased sig-
naling through the p44/42 mitogen-activated protein
kinase (MAPK) pathway [27]. High levels of expression of
c-erbB-2 (HER-2/neu), and the homologous c-erbB-1, is a
poor prognostic sign, and signaling from these receptors
occurs in part through p44/42 MAPK. Furthermore, ele-
vated p44/42 MAPK activity alone has been suggested to
have prognostic significance for disease-free survival
(reviewed in [28]), and therefore interruption of such sig-
naling, such as by proteasome inhibition, would seem to
hold promise for breast cancer therapy.
Proteasome inhibitors may also be effective in breast
cancer treatment by helping to overcome some of the
major pathways by which cancer cells resist the action of
chemotherapy. Two of these have already been referred to
above, in that both signaling through NF-κB and p44/42
MAPK can be anti-apoptotic. Chemotherapeutic agents
such as taxanes and anthracyclines have been shown to
activate one or both of these pathways, potentially limiting
their own ability to induce tumor cell death. Since protea-
some inhibitors block these pathways, they may be able to
not only activate apoptosis, but also enhance the antitu-
mor activity of drugs such as paclitaxel and doxorubicin.
Another important mechanism of resistance to chemo-
therapy is the expression by cancer cells of the P-glyco-
protein, a membrane pump that promotes the efflux of
xenobiotics such as chemotherapy drugs, decreasing their
intracellular concentration and effectiveness. Proteasome
function is necessary for normal maturation of P-glyco-
protein. Proteasome inhibition could decrease the accu-
mulation of P-glycoprotein in the membranes of cancer
cells, thereby preventing it from ridding these cells of
chemotherapy drugs, resulting in increased tumor killing.
Preclinical studies
Because of the promising rationale described above, a
variety of proteasome inhibitors, most commonly based on
short peptides, have been synthesized and evaluated
using in vitro and in vivo model systems. The best studied
of these in models of breast cancer, and in clinical trials as
described below, has been Millennium Pharmaceuticals’
bortezomib (Velcade™; previously known as PS-341, LDP-
341, and MLN-341). This drug decreased the survival of
both cultured MCF-7 cells derived from human breast
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cancer and of EMT-6/Parent mouse mammary carcinoma
xenograft tumors in a dose-dependent fashion. PS-341
also increased the ability of radiation or cyclophos-
phamide to kill tumor cells in this model system [29].
In our laboratory we have been interested in combinations
of PS-341 with anthracyclines, given the prominent role of
the latter group of agents in breast cancer therapy. We
have especially focused on liposomal doxorubicin, or
Doxil®, because of this drug’s activity in refractory breast
cancer, its ease of administration (with dosing once every
three to four weeks), and its favorable toxicity profile.
Using a BT-474-based xenograft model of human breast
cancer, we have found that the combination of PS-341
and Doxil® results in enhanced antitumor efficacy, and
increased apoptosis when compared with that obtained
using either agent alone (Fig. 2).
Clinical trials
More than 400 patients in the United States have been
treated in Phase I and Phase II clinical trials of PS-341,
which is given by intravenous push once or twice weekly.
In the twice weekly for two weeks out of three schedule
which has been used most often, the maximum tolerated
dose in patients with solid tumors has been defined to be
1.3 mg/m2 [30]. Because of significant activity against
multiple myeloma seen in Phase I trials [3], Phase II [31]
and Phase III studies of PS-341 are being pursued or
planned for use against multiple myeloma. Preclinical data
in chronic lymphocytic leukemia have also been encourag-
ing, and Phase II trials of PS-341 are being pursued to
treat this disease as well.
In Phase I studies of PS-341 as a single agent in patients
with solid tumors, rare responses have been seen in
cancers of the prostate, kidney, head and neck, and lung.
Given its potential to enhance chemosensitivity, however,
PS-341 is being combined with conventional agents in
several ongoing Phase I studies. Some of these combina-
tion regimens hold promise for breast cancer treatment.
For example, given the preclinical data supporting a
Doxil®/PS-341 combination discussed above, a Phase I
clinical trial of this combination is being conducted at the
University of North Carolina at Chapel Hill. Similarly, a
Phase I study of the combination of doxorubicin and PS-
341 is ongoing at the University of Wisconsin [32]. The
combination of paclitaxel and PS-341 is being studied at
the Ohio State University (C Shapiro, personal communi-
cation). There are also currently ongoing Phase I trials of
PS-341 in combination with 5-fluorouracil [33], irinotecan
[34], and gemcitabine [35]. Preliminary data from these
trial centers suggest that their respective combinations
have been tolerated well so far. While all of these are
Phase I studies that will enroll a variety of solid-tumor
patients, at least some of the sites plan to focus on breast
cancer patients, particularly once the maximum tolerated
dose has been identified. This should enable preliminary
evidence of antitumor activity to be obtained in this patient
population in preparation for Phase II efficacy studies.
Future directions
Currently available drugs that most specifically target the
ubiquitin-proteasome pathway, such as PS-341, focus
predominantly on the proteasome itself. Research into the
machinery responsible for ubiquitination has lagged some-
what in the past, but interest in this area has recently
grown greatly. Inhibition of the E1 ubiquitin-activating
enzyme would have effects on normal and neoplastic cells
that would, in some ways, be even more broad-ranging
than proteasome inhibitors. Drugs that would inhibit or
stimulate specific E3 ubiquitin ligases, however, could
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Figure 2
The combination of PS-341 and Doxil® induces enhanced apoptosis in
vivo. The impact of vehicle, PS-341 alone, Doxil® alone, or the
combination, was studied in a murine xenograft model of human breast
cancer established using BT-474 breast carcinoma cells. Apoptosis
was evaluated in tumor sections 24 hours after the indicated
treatments by detection of single stranded DNA fragmentation using
the murine monoclonal antibody Mab 3299 [45] (Chemicon
International, Temecula, CA, USA). Single stranded DNA associated
with programmed cell death (red) is shown, along with total nuclear
DNA (blue), the latter detected using 4,6-diamidino-2-phenylindole
(Vector Laboratories, Burlingame, CA, USA). Slides were visualized
using an ultraviolet Zeiss Axioplan fluorescence microscope (Carl
Zeiss Optical, Inc., Chester, VA, USA). Separate photographs were
taken with appropriate filters for blue nuclear staining and red single-
stranded-DNA staining, overlayed using Adobe Photoshop software,
and displayed as a fusion image at 10× magnification.6
have an impact upon a much more restricted set of pro-
teins, and could be more specifically targeted and better
tolerated clinically. One interesting potential target would
be MDM2, which is overexpressed in some human breast
tumors [36]. MDM2 is an E3 protein responsible for p53
degradation. Inhibition of MDM2 should result in increased
levels of p53, prompting cell-cycle arrest, apoptosis, and
possibly enhanced chemosensitivity in breast tumors with
wild-type p53. Inhibitors such as these are currently being
actively sought, and hopefully will soon be available for
preclinical and clinical trials.
A second interesting target in this same light would be the
F-box protein FWD-1, which mediates ubiquitination of the
IκB α, β, and ε proteins [37]. Inhibitors of this component
of the SCF(FWD1) complex would provide a more spe-
cific means of inhibiting NF-κB, and might sensitize cells
to chemotherapy, as described earlier.
Finally, p27Kip1 could also be targeted. This cyclin-depen-
dent kinase inhibitor is present at low levels in aggressive
carcinomas. Its expression level, therefore, may have prog-
nostic significance in breast cancer (reviewed in [38]).
Since this protein is ubiquitinated by SCF(Skp2) in at
least some phases of the cell cycle [39,40], inhibition of
this complex could result in accumulation of p27 and con-
sequent cell-cycle arrest and apoptosis.
Ubiquitination could also be influenced by impacting upon
related pathways, such as protein modification by the
small ubiquitin-like modifier-1 (SUMO-1). SUMOlation of
ΙκΒα prevents its subsequent ubiquitination, thereby sta-
bilizing its association with NF-κB [41]. Thus, stimulation
of SUMOlation of IκBα could provide another mechanism
of inhibiting nuclear NF-κB translocation and enhancing
chemosensitivity. Interestingly, inhibition of SUMOlation
may have some benefits as well, especially in combination
with Top-1 inhibitors. Treatment of cells with camptothecin
results in conjugation of Top-1 with SUMO-1, which is a
possible repair response to topoisomerase-mediated DNA
damage [42]. Thus, inhibitors of this repair mechanism
may enhance sensitivity to agents such as irinotecan.
Conclusions
The ubiquitin-proteasome pathway is just beginning to be
exploited as a target for cancer therapy. Nonetheless,
given the available molecular biological, preclinical, and
clinical data, there is very good reason to be optimistic
that current drugs and future candidates will contribute
significantly to the care of patients with breast cancer.
Agents such as the proteasome inhibitor PS-341 are
already undergoing clinical trials, and data concerning the
Phase I safety and Phase II efficacy of combinations with
other antineoplastic agents will be forthcoming over the
next several years. This period should prove to be an excit-
ing era for this field of research.
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